| Actemra SC (tocilizumab SC) / Roche, Halozyme |
ACTRN12621001695897: A randomised controlled trial to compare drug dose reduction strategies in adults with rheumatoid arthritis and psoriatic arthritis for safer and more efficient drug use |
|
|
| Recruiting | 4 | 324 | | | University of Sydney, Australian Government, Department of Health, National Health and Medical Research Council, Medical Research Future Fund (MRFF) | Rheumatoid arthritis, Psoriatic arthritis | | | | |
| Recruiting | 4 | 98 | Europe | Tocilizumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development | Rheumatoid Arthritis | 12/24 | 12/24 | | |
| Recruiting | 4 | 224 | Europe | Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia | Lille Catholic University | Arthritis, Rheumatoid | 09/24 | 11/24 | | |
REPAIR, NCT02765074: Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis |
|
|
| Recruiting | 4 | 60 | Europe | subcutaneous tocilizumab, Roactemra | Centre Hospitalier Régional d'Orléans, Rennes University Hospital | Rheumatoid Arthritis | 06/25 | 06/25 | | |
2016-002716-41: A STUDY TO EVALUATE LONG TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE |
|
|
| Not yet recruiting | 3 | 10 | Europe | Solution for injection, RoActemra 162 mg solution for injection in pre-filled syringe | ROCHE SAS, ROCHE SAS | Giant cell arteritis (GCA), An inflammatory disease of the blood vessels that typically occurs in individuals over 50 years of age. It can cause fever, headache, jaw or mouth pain and can lead to irreversible vision loss, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT06048224: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 669 | RoW | HS628+MTX, Actemra +MTX | Zhejiang Hisun Pharmaceutical Co. Ltd. | Moderate to Severe Active Rheumatoid Arthritis | 09/21 | 01/22 | | |
TRANSFORM, NCT05090410: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate |
|
|
| Recruiting | 3 | 400 | Japan | filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly | Atsushi Kawakami, Gilead Sciences | Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound, Biomarker | 02/23 | 12/23 | | |
NCT05725434: A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis |
|
|
| Not yet recruiting | 3 | 30 | NA | CT-P47 AI (tocilizumab), CT-P47 PFS (tocilizumab) | Celltrion | Rheumatoid Arthritis | 04/23 | 07/23 | | |
TOGIAC, NCT04888221: Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement |
|
|
| Recruiting | 3 | 66 | Europe | Tocilizumab, RoActemra, Actemra, Placebo | Assistance Publique - Hôpitaux de Paris, Roche Chugai, Roche Pharma AG | Giant Cell Arteritis, Neurovascular Disorder | 03/24 | 03/24 | | |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 10/25 | 10/25 | | |
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | 3 | 90 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, ABT-494, Tocilizumab | AbbVie | Juvenile Idiopathic Arthritis | 02/27 | 06/29 | | |
2018-000391-15: Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumab in subjects with refractory myositis Studio multicentrico, prospettico in aperto per valutare l’efficacia e la sicurezza di Tocilizumab in soggetti con miosite refrattaria |
|
|
| Not yet recruiting | 2 | 16 | Europe | RoActemra 162 mg soluzione iniettabile in siringa preriempita, NA, Solution for injection, RoActemra 162 mg soluzione iniettabile in siringa preriempita | Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, AIFA (Agenzia Italiana del Farmaco) | Myositis (dermatomyositis [DM] or polymyositis [PM]) Miositi: Dermatomiosite (DM) e Polimiosite (PM), Chronic inflammatory disorders of striated muscle with variable involvement of internal organs Patologie infiammatorie croniche del muscolo striato con variabile interessamento degli organi interni, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Recruiting | 2 | 58 | Europe | tocilizumab and IV steroids combination, IV steroids combination alone | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Roche Chugai | Giant Cell Arteritis, Optic Ischaemic Neuropathy | 11/20 | 12/22 | | |
NCI-2021-04325, NCT04940299: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
|
|
| Active, not recruiting | 2 | 35 | US | Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Tocilizumab, Actemra, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra | M.D. Anderson Cancer Center | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma | 12/24 | 12/24 | | |
UVB, NCT05874505: "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease" |
|
|
| Not yet recruiting | 2 | 60 | NA | Adalimumab, Tocilizumab | Assistance Publique - Hôpitaux de Paris | Behcet's Uveitis | 11/26 | 07/27 | | |
ACTRN12621000663853: A single dose phase 1 study to evaluate safety and Pharmacokinetics of three tocilizumab products in normal healthy volunteers |
|
|
| Active, not recruiting | 1 | 300 | | | Dr. Reddy’s Laboratories Ltd., Biologics, Dr. Reddy’s Laboratories Ltd., Biologics | Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA) | | | | |
NCT05188378: A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects |
|
|
| Recruiting | 1 | 300 | RoW | CT-P47, EU-approved RoActemra, | Celltrion | Healthy Subjects | 10/22 | 01/23 | | |
NCT05968508: A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects |
|
|
| Recruiting | 1 | 300 | RoW | BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) | Bio-Thera Solutions | Healthy Men | 12/24 | 04/25 | | |
NCT04885829: Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers |
|
|
| Completed | 1 | 300 | RoW | Tocilizumab Prefilled Syringe, Actemra, RoActemra | Syneos Health, Dr. Reddy's Laboratories Limited | Rheumatoid Arthritis, Giant Cell Arteritis | 05/23 | 05/23 | | |
ISRCTN17975931: A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma |
|
|
| Recruiting | 1 | 36 | Australia, Belgium, Denmark, Italy, Poland, Spain, US | Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Columvi (glofitamab) - Roche, dexamethasone - Generic mfg., Actemra IV (tocilizumab) - Roche, JW Pharma, Actemra SC (tocilizumab SC) - Roche, Halozyme | Genentech, Inc;Genentech, Genentech | B-cell non-Hodgkin lymphoma | | | | |
NL-TCZ-12280, NCT06262477: A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants |
|
|
| Recruiting | 1 | 300 | US | BIIB800, BAT1806, Actemra, Tocilizumab, RoActemra | Biogen | Healthy Volunteer | 11/24 | 11/24 | | |
| Not yet recruiting | N/A | 2000 | NA | care strategy | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Groupe Hospitalier Pitie-Salpetriere | Non-infectious Uveitis | 08/28 | 08/28 | | |
NCT04505982: Anti IL6R Reduce Complement Serum Level in Rheumatoid Arthritis Patients: Facts and Implications |
|
|
| Recruiting | N/A | 35 | Europe | Data extraction from medical files | BADOT, Valerie | Rheumatoid Polyarthritis | 12/20 | 12/20 | | |